October 28th, 2026ACOG advises against GLP-1 receptor agonists during pregnancyACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.Read more
October 27th, 2026Multi-society framework ties cardiovascular risk to female life stagesJoint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.Read more
October 24th, 2026TMS 2026: HSDD biopsychosocial approach, night sweats red flags, misread WHI dataGet caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California. Read more
October 23rd, 2026Hormone therapy linked to greater migraine burden after menopauseHormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.Read more
October 22nd, 2026Neurokinin receptor antagonists improve menopausal sleep disturbanceNK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.Read more
October 22nd, 2026Higher physical activity tied to lower perimenopause symptom burdenPerimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.Read more
October 21st, 2026Wearables may add insight into perimenopausal sleep complaintsPerimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.Read more
October 21st, 2026Pooled OASIS data: 66.9% achieve ≥50% VMS reduction with elinzanetantElinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.Read more